Search clinical trials for: BP101

Total 104 results

Ivix LLX

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers

Hypoactive Sexual Desire Disorder(HSDD)

Russian Federation
Ivix LLX

Completed

Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire

Hypoactive Sexual Desire Disorder (HSDD)

Russian Federation
Ivix LLX

Completed

BP101 for Adults With Female Sexual Dysfunction

Female Sexual Dysfunction | Hypoactive Sexual Desire Disorder | Sexual Desire Disorder

Russian Federation
Finch Research and Development LLC.

Terminated

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) (PRISM4)

Recurrent C. Difficile Infection

United States, Canada
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics

Advanced Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Advanced Solid Tumors

China
Universidad Complutense de Madrid

Recruiting

Ligilactobacillus Salivarius MP101 for Elderly in a Nursing Home (PROBELDERLY)

Covid19

Spain
Zhe Jiang Hisun Bioray Bio-pharmaceu tical Co.Ltd

Recruiting

A Phase I Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Pharmacokinetic Study of TQB3101 in Chinese Healthy Subjects

Pharmacokinetic Study

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Advanced Malignant Tumor

China
Finch Research and Development LLC.

Withdrawn

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT) (SPROUT)

Autism Spectrum Disorder | Autism | ASD | FMT | Fecal Transplant | Autistic Thinking | Autistic Behavior | Fecal Microbiota Transplant | Finch | CP101 | SPROUT
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Lung Neoplasms

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)

Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)

China
NuPathe Inc.

Completed

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months (NP101-009)

Migraine Disorders

United States
NYU Langone Health

Withdrawn

Brijjit® for Wound Closure in Gender Affirming Mastectomies

Mastectomy

United States
Panolos Bioscience

Recruiting

Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent

Metastatic Colorectal Cancer | Hepatocellular Carcinoma | Gastric Cancer | Solid Tumor | Advanced Solid Tumor | Solid Tumor, Adult

Korea, Republic of
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

Cervical Cancer

China
NuPathe Inc.

Completed

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months (NP101-008)

Migraine Disorders

United States
Bio-Path Holdings, Inc.

Completed

Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

Recurrent Adult Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Ph1 Positive CML

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

Metastatic Colorectal Cancer (mCRC)

China
Bio-Path Holdings, Inc.

Withdrawn

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia, Ph1-Positive

United States
Bio-Path Holdings, Inc.

Recruiting

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

Fallopian Tube Neoplasms | Carcinoma, Ovarian Epithelial | Solid Tumor | Endometrial Cancer | Peritoneal Cancer | Solid Tumor, Adult

United States
Bio-Path Holdings, Inc.

Recruiting

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Acute Myeloid Leukemia (AML)

United States
NuPathe Inc.

Completed

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine (NP101-007)

Migraine Disorders

United States
Finch Research and Development LLC.

Completed

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff (PRISM3)

Clostridium Difficile Infection Recurrence

Canada, United States
Finch Research and Development LLC.
Medpace, Inc.

Completed

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection (PRISM-EXT)

Clostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota | Fecal Transplant

United States, Canada
BioNova Pharmaceuticals (Shanghai) LTD.

Completed

Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

GVHD, Chronic

China
Fudan University

Recruiting

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Triple-negative Breast Cancer

China
Second Affiliated Hospital, School of Medicine,...
BoYuan RunSheng Pharma (Hangzhou) Co., Ltd.

Unknown

Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma

Recurrent Glioblastoma | Refractory Glioblastoma

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Redwood Pharma AB
Cross Research S.A.

Completed

Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome

Dry Eye Syndromes

Austria, Germany, Hungary
Robert Feldman

Terminated

The American Glaucoma Society (AGS) Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study (ASSISTS) (ASSISTS)

Glaucoma

United States
Emory University

Withdrawn

Microporous Polysaccharide Hemospheres Epistaxis

Epistaxis

United States
NuPathe Inc.

Completed

Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults

Compare Bioequivalence Patches Previously Used in the NP101-007 Study

United States
West China Hospital

Not yet recruiting

SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer

Colorectal Cancer
NuPathe Inc.

Completed

Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine

Acute Migraine
SciClone Pharmaceuticals

Terminated

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine (RP101)

Pancreatic Cancer

United States, Chile, Spain, Brazil, Argentina, France, Germany, Hungary, Netherlands, Peru, Poland, Romania, United Kingdom
NuPathe Inc.

Completed

Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers (NP101-006)

Migraine Disorders

United States
NuPathe Inc.

Completed

Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period (NP101-011)

Migraine Disorders

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC

Non-small Cell Lung Cancer(NSCLC)

China
University of Khartoum

Completed

Efficacy of Different Drugs to Control Post Root Canal Treatment Pain

Pain | Postoperative Pain | Irreversible Pulpitis

Sudan
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Colorectal Carcinoma | Refractory Colorectal Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Refractory Melanoma | BRAF V600 Wild Type | Intracranial Melanoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7 | EGFR Exon 19 Deletion Mutation | EGFR NP_005219.2:p.L858R

United States
M.D. Anderson Cancer Center

Recruiting

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type

United States
Fudan University

Recruiting

Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (BCTOP-T-M01)

Triple-Negative Breast Cancer

China

Search clinical trials for: BP101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations